Showing 3111-3120 of 5016 results for "".
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://practicaldermatology.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- Dr. Sheila Fallon Friedlander Highlights Pediatric Prevention, Guidelines, and Practical Care at Maui Derm Hawaiihttps://practicaldermatology.com/news/dr-sheila-fallon-friedlander-highlights-pediatric-prevention-guidelines-and-practical-care-at-maui-derm-hawaii/2485512/Giving clinicians tools they can use “in the here and now” was the theme as Sheila Fallon Friedlander, MD, presented on pediatric dermatology in one of the opening talks at Maui Derm Hawaii 2026. Dr. Friedlander covered prevention strategies, recent guideline updates, treatment safety (esp
- OX40‑Targeted Therapy Among Dr. Hensin Tsao’s Highlights at Maui Derm Hawaii 2026https://practicaldermatology.com/news/ox40targeted-therapy-among-dr-hensin-tsaos-highlights-at-maui-derm-hawaii-2026/2485510/A novel immune pathway that may redefine atopic dermatitis (AD) treatment paradigms was among the highlights presented by Hensin Tsao, MD, in his conference-opening presentation at Maui Derm Hawaii 2026. Melanoma immunotherapy and various other topics were covered, but perhaps the most pot
- Analysis: Machine Learning Model Outperforms Existing Melanoma Prognostic Toolshttps://practicaldermatology.com/news/analysis-machine-learning-model-outperforms-existing-melanoma-prognostic-tools/2484593/A new machine learning-based model may offer clinicians a more accurate method for predicting prognosis in patients with cutaneous melanoma, according to a study published in Experimental Dermatology.
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://practicaldermatology.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Study: Low-Calorie Diet May Increase PsA Riskhttps://practicaldermatology.com/news/study-low-calorie-diet-may-increase-psa-risk/2483973/A low-calorie diet may increase the risk of developing psoriatic arthritis, according to findings from a Mendelian randomization (MR) study published in Clinical, Cosmetic and Investigational Dermatology.
- Low Recurrence Observed in MIS Cases With Clear Biopsy Marginshttps://practicaldermatology.com/news/low-recurrence-observed-in-mis-cases-with-clear-biopsy-margins/2483319/A new retrospective cohort study suggests that diagnostic excisional biopsy alone maya be efficacious for select cases of melanoma in situ (MIS) that are neither lentigo maligna (LM) nor acral lentiginous melanoma (ALM) subtypes.
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo